Skye Bioscience and Redx Pharma announced they have entered into a definitive transaction agreement, under which Skye will acquire Redx. Skye hosted an associated webcast discussing the transaction (view slides). The combined company plans to operate under the name Fibrx Therapeutics and trade on Nasdaq. Below, FENIX provides highlights and insights into the agreement.